Stay updated on Ribociclib Efficacy After CDK4/6 Inhibit Progression Clinical Trial
Sign up to get notified when there's something new on the Ribociclib Efficacy After CDK4/6 Inhibit Progression Clinical Trial page.

Latest updates to the Ribociclib Efficacy After CDK4/6 Inhibit Progression Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedThe page has been updated to reflect a new version of the trial documentation (v2.15.0) and includes the name of the principal investigator, Melissa Accordino, MD, from Columbia University, as well as the addition of the term 'Metastatic Breast Cancer' and the trial identifier 'AAAP9506'.SummaryDifference52%
- Check34 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check41 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check77 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference0.9%
- Check92 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference0.9%
Stay in the know with updates to Ribociclib Efficacy After CDK4/6 Inhibit Progression Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ribociclib Efficacy After CDK4/6 Inhibit Progression Clinical Trial page.